Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Authors
Valle, Juan WWasan, H
Lopes, A
Backen, Alison C
Palmer, D
Morris, Karen
Duggan, M
Cunningham, D
Anthoney, D
Corrie, P
Madhusudan, S
Maraveyas, A
Ross, P
Waters, J
Steward, W
Rees, C
Beare, S
Dive, Caroline
Bridgewater, J
Affiliation
Institute of Cancer Studies, University of Manchester, Manchester, UKIssue Date
2015-08
Metadata
Show full item recordAbstract
Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on progression-free survival.Citation
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. 2015, 16 (8):967-78 Lancet OncolJournal
The Lancet. OncologyDOI
10.1016/S1470-2045(15)00139-4PubMed ID
26179201Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00139-4